Adalvo announces DCP approval for Dimethyl Fumarate 120mg, 240mg hard capsules
Adalvo has announced a successful DCP closure of our Dimethyl Fumarate 120mg, 240mghard capsules in Europe.
Adalvo's product has been developed based on the reference brand Tecfidera, which is indicated in the treatment of elapsing remitting multiple sclerosis. The product sold at around $2.8 billion globally in 2021, according to IQVIA.
Adalvo believes that to be one of the first Companies to receive an EU approval and based on this positive news, Adalvo will proceed to launch this product, within respective markets, as soon as regulatory exclusivities and patents allow us.
Apart from Dimethyl Fumarate, Adalvo is targeting to be among the first companies to launch Teriflunomide and Cladribine. Our teams will be available to share more details.
Disclaimer: Dimethyl Fumarate which is subject to patent protection is currently not offered or made available in countries where patents are in force.
Fur further information visit Adalvo.com